Adaptimmune Therapeutics Gets FDA Priority Review Approval for Sarcoma License Application
Provided by
Dow Jones
By Sabela Ojea
Adaptimmune Therapeutics said the Food and Drug Administration accepted for priority review its biologics license application to treat advanced synovial sarcoma, a rare type of cancer.
The clinical-stage biopharmaceutical company on Wednesday said its afami-cel therapy has a prescription drug user fee act target action date set for Aug. 4.
"If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade," the company said.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
January 31, 2024 18:40 ET (23:40 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Amazon Earnings: AWS Growth Accelerates and Profit Margins Improve
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?